FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to medicine, in particular to gynecology and deals with hormonal treatment of disease or disorder and increase of fertility in woman who needs it. For this purpose, regimens of continuous with more than 50-day duration introduction of combination of ethinylestradiole in dose from 5 mcg to 50 mcg and levonorgestrel in dose from approximately 0.05 mg to approximately 1.5 mg is suggested. Further, estrogen is introduced during period from 2 to 10 successive days.
EFFECT: due to "estrogen bridge" between cycles of hormonal therapy, inventions ensure reduction of number of unplanned bleedings in second and following cycles of intake in comparison with regimens, which include after the cycle finishing days, free of hormonal therapy, and minimisation of symptoms, conditioned by break between cycles.
64 cl, 10 dwg, 21 tbl, 10 ex
